Promoted Content
Promoted Content

Find Approved Gastroenterology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Bismuth Subsalicylate

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Arcadia Consumer Healthcare

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 20, 2020

            Details:

            Acquisition further strengthens Arcadia's consumer healthcare product portfolio.

            Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

            Contact the Supplier

            Lead Product(s): Lansoprazole

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.

            Virtual BoothA global leader in antibiotics.

            Contact the Supplier

            Lead Product(s): Pantoprazole Sodium

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Civica Rx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 02, 2020

            Details:

            Sandoz has shipped pantoprazole sodium for injection, 40 mg to Civica Rx to supply the hospitals it serves as part of a multiyear collaboration to help reduce supply shortages, with several other medicines on the way before the end of the year.

            Virtual BoothA global leader in antibiotics.

            Contact the Supplier

            Lead Product(s): Naldemedine Tosylate

            Therapeutic Area: Gastroenterology Product Name: Rizmoic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            Based on Phase 3 trial data, Rizmoic has been shown to increase the frequency of bowel movements compared to placebo in patients either with cancer or chronic non-cancer pain who had previously received laxative treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adalimumab

            Therapeutic Area: Gastroenterology Product Name: Humira

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2021

            Details:

            Approval for adalimumab based on results from the pivotal Phase 3 ENVISION I study showing the higher dosage of HUMIRA induced clinical remission in 60 percent of patients at Week 8 and 45 percent of patients, who responded at Week 8, were in remission at Week 52.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nitazoxanide

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2021

            Details:

            Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.